Opus Genetics, Inc. IRD 深 沪
等待开盘 02-10 09:30:00 美东时间
3.38
+0.370
+12.29%
华盛通- 最 高3.385
- 今 开3.01
- 成交量 235.60万股
- 最 低 3.01
- 昨 收 3.01
- 总市值 2.33亿
- 52周最高 3.385
- 市盈率 静 --
- 换手率 3.42%
- 52周最低 0.65
- 委 比 -34.70%
- 总股本 6896.42万
- 历史最高 23.08
- 量 比 1.61
- 振 幅 12.46%
- 历史最低 0.65
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
BTIG Reiterates Buy on Opus Genetics, Maintains $7 Price Target
BTIG analyst Thomas Shrader reiterates Opus Genetics (NASDAQ:IRD) with a Buy and maintains $7 price target.
01-28 18:08
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
BTIG Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $7
BTIG analyst Thomas Shrader initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating and announces Price Target of $7.
01-20 18:13
Opus Genetics Expects To Announce BEST1 Clinical Data In 2026, Advance LCA5 Program Into Pivotal Testing Toward FDA Approval
Opus Genetics, Inc. (NASDAQ:IRD) (the "Company," "Opus," or "Opus Genetics"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited
01-08 20:17
Opus Genetics Highlights Multi‑Asset Pipeline With 2026 Data Readouts, Ophthalmic Gene Therapy Trials, sNDA For Presbyopia, And JPM Healthcare Conference Presentation
- Multi-asset pipeline with significant targeted data readouts and milestones -- Two lead ophthalmic gene therapy programs in clinical trials with new data anticipated in 2026 -- Supplemental New Drug Application (sNDA)
01-08 20:15
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
Opus Genetics Says IDMC Issues Positive Recommendation To Continue As Planned In Phase 1/2 BEST1 Clinical Trial, Evaluating Opgx-BEST1 In Participants With Best Disease
Opus Genetics (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases
2025-12-09 20:06
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
Piper Sandler Initiates Coverage On Opus Genetics with Overweight Rating, Announces Price Target of $7
Piper Sandler analyst Biren Amin initiates coverage on Opus Genetics (NASDAQ:IRD) with a Overweight rating and announces Price Target of $7.
2025-11-25 22:27
